Unnamed: 0,title,date,stock,sentiment
416289.0,UPDATE: Endologix Forbearance Deal Informed Parties Co. 10-Q Filing Would Include Statement There Is Substantial Doubt Regarding Co.'s Ability To Continue As Going Concern,2020-05-28 06:14:00-04:00,ELGX,positive
416290.0,"Endologix 8-K Shows Co. Entered Forbearance Deal To Credit Agreement With Lenders Party, Deerfield ELGX Revolver",2020-05-28 06:13:00-04:00,ELGX,positive
416291.0,Endologix Granted US Patent 'Catheter system and methods of using same',2020-05-26 13:32:00-04:00,ELGX,positive
416292.0,BTIG Downgrades Endologix to Neutral,2020-05-12 07:19:00-04:00,ELGX,neutral
416293.0,"Endologix Q1 EPS $(0.900) Misses $(0.240) Estimate, Sales $28.510M Miss $29.700M Estimate",2020-05-11 16:02:00-04:00,ELGX,negative
416294.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,ELGX,neutral
416295.0,"Endologix Granted Patent Titled 'Bifurcated Stent Grafts, Stents, And Methods'",2020-04-30 15:39:00-04:00,ELGX,positive
416296.0,"Endologix Sees Prelim. Q1 Sales ~$28.5M; Says Cash, Equivalents And Restricted Cash As Of Mar. 31 Are Expected To Be $42.4M",2020-04-06 08:29:00-04:00,ELGX,negative
416297.0,"Stephens & Co. Maintains Equal-Weight on Endologix, Lowers Price Target to $2",2020-03-23 11:27:00-04:00,ELGX,negative
416298.0,Endologix Earlier Adds Jane E. Kiernan To Its Board Of Directors,2020-03-18 09:26:00-04:00,ELGX,neutral
416299.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,ELGX,negative
416300.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ELGX,negative
416301.0,Endologix Reports Debt Restructuring To Address 2020 Maturities,2020-02-24 08:55:00-05:00,ELGX,negative
416302.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,ELGX,negative
416303.0,"Stephens & Co. Maintains Equal-Weight on Endologix, Lowers Price Target to $3",2020-02-20 06:28:00-05:00,ELGX,negative
416304.0,"Endologix Q4 EPS $(0.4) Beats $(0.68) Estimate, Sales $35.8M Beat $34.34M Estimate",2020-02-19 16:04:00-05:00,ELGX,neutral
416305.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,ELGX,negative
416306.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,ELGX,positive
416307.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,ELGX,positive
416308.0,Stocks That Hit 52-Week Lows On Tuesday,2020-02-11 11:05:00-05:00,ELGX,negative
416309.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,ELGX,positive
416310.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,ELGX,negative
416311.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-06 10:53:00-05:00,ELGX,negative
416312.0,"Endologix Sees Prelim. Q4 Sales $35.8M vs $36.75M Est., FY19 Sales $143.4M vs $142.06M Est.",2020-02-06 08:37:00-05:00,ELGX,neutral
416313.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,ELGX,negative
416314.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,ELGX,neutral
416315.0,Stocks That Hit 52-Week Lows On Tuesday,2020-02-04 11:05:00-05:00,ELGX,negative
416316.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,ELGX,negative
416317.0,Stocks That Hit 52-Week Lows On Friday,2020-01-31 11:00:00-05:00,ELGX,negative
416318.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,ELGX,negative
416319.0,Stocks That Hit 52-Week Lows On Thursday,2020-01-30 10:54:00-05:00,ELGX,negative
416320.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,ELGX,positive
416321.0,Stocks That Hit 52-Week Lows On Wednesday,2020-01-29 10:52:00-05:00,ELGX,negative
416322.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,ELGX,neutral
416323.0,Stocks That Hit 52-Week Lows On Tuesday,2020-01-28 11:09:00-05:00,ELGX,negative
416324.0,"Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference",2020-01-02 16:03:00-05:00,ELGX,neutral
416325.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,ELGX,negative
416326.0,Stocks That Hit 52-Week Lows On Friday,2019-12-20 12:13:00-05:00,ELGX,negative
416327.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,ELGX,negative
416328.0,Stocks That Hit 52-Week Lows On Wednesday,2019-12-18 13:51:00-05:00,ELGX,negative
416329.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,ELGX,positive
416330.0,68 Biggest Movers From Yesterday,2019-12-18 04:56:00-05:00,ELGX,neutral
416331.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-12-17 12:01:00-05:00,ELGX,neutral
416332.0,Stocks That Hit 52-Week Lows On Tuesday,2019-12-17 12:01:00-05:00,ELGX,negative
416333.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,ELGX,positive
416334.0,Stocks That Hit 52-Week Lows On Wednesday,2019-12-11 10:55:00-05:00,ELGX,negative
416335.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,ELGX,negative
416336.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,ELGX,positive
416337.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,ELGX,neutral
416338.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,ELGX,neutral
416339.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,ELGX,neutral
416340.0,Endologix Sees Q4 Sales $32.5M-35.5M vs $35.51M Est,2019-11-06 16:59:00-05:00,ELGX,neutral
416341.0,"Endologix Reaffirms 2019 Sales Guidance, Sees Revenue at Least $140M vs $142.65M Est.",2019-11-06 16:58:00-05:00,ELGX,neutral
416342.0,"Endologix Q3 EPS $(0.55) Beats $(0.72) Estimate, Sales $35.775M Beat $35.38M Estimate",2019-11-06 16:57:00-05:00,ELGX,neutral
416343.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,ELGX,positive
416344.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,ELGX,positive
416345.0,"Endologix, Commenting On FDA Update On Type III Endoleaks With AFX Endovascular AAA System Says Current Commercially Available Versions Of AFX Systems Are Manufactured Using A Different Eptfe Processing Methodology Than AFX Strata",2019-10-29 07:13:00-04:00,ELGX,neutral
416346.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,ELGX,neutral
416347.0,"FDA Says New Information Suggests There May Be Higher Risk Of Type III Endoleaks With Use OF Endologix AFX With Duraply, AFX2 Endovascular Grafts",2019-10-28 12:16:00-04:00,ELGX,negative
416348.0,FDA Issues Safety Communication Giving New Information On Risks For Patients With Endovascular Grafts Made By Endologix,2019-10-28 12:16:00-04:00,ELGX,positive
416349.0,Stocks That Hit 52-Week Lows On Friday,2019-10-25 12:49:00-04:00,ELGX,negative
416350.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,ELGX,negative
416351.0,42 Biggest Movers From Yesterday,2019-10-04 04:36:00-04:00,ELGX,neutral
416352.0,28 Stocks Moving In Thursday's Mid-Day Session,2019-10-03 12:45:00-04:00,ELGX,neutral
416353.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,ELGX,negative
416354.0,46 Biggest Movers From Yesterday,2019-10-03 05:05:00-04:00,ELGX,neutral
416355.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,ELGX,negative
416356.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,ELGX,negative
416357.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,ELGX,positive
416358.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,ELGX,positive
416359.0,46 Biggest Movers From Yesterday,2019-09-20 04:45:00-04:00,ELGX,neutral
416360.0,"The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO",2019-09-19 07:39:00-04:00,ELGX,neutral
416361.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,ELGX,neutral
416362.0,Stocks That Hit 52-Week Lows On Thursday,2019-09-12 13:41:00-04:00,ELGX,negative
416363.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,ELGX,neutral
416364.0,"The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication",2019-09-06 07:27:00-04:00,ELGX,neutral
416365.0,"The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug",2019-09-05 08:12:00-04:00,ELGX,neutral
416366.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,ELGX,neutral
416367.0,25 Stocks Moving In Friday's Pre-Market Session,2019-06-07 08:04:00-04:00,ELGX,neutral
416368.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,ELGX,positive
416369.0,Endologix shares are trading higher after the company reported an reinstatement of a CE mark for its Nellix EndoVascular Aneurysm Sealing System.,2019-06-06 16:04:00-04:00,ELGX,positive
416370.0,Endologix Reports Reinstatement Of CE Mark For Nellix EndoVascular Aneurysm Sealing System,2019-06-06 16:01:00-04:00,ELGX,neutral
416371.0,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen",2019-05-03 07:49:00-04:00,ELGX,positive
416372.0,Endologix Reaffirms FY19 Revenue Guidance Of Atleast $140M Vs. $141.31M Estimate,2019-05-02 16:43:00-04:00,ELGX,neutral
416373.0,Endologix Q1 Sales $35.6M Beat $34.43M Estimate,2019-05-02 16:42:00-04:00,ELGX,neutral
416374.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,ELGX,positive
416375.0,58 Biggest Movers From Yesterday,2019-04-02 05:45:00-04:00,ELGX,neutral
416376.0,46 Stocks Moving In Monday's Mid-Day Session,2019-04-01 13:06:00-04:00,ELGX,neutral
416377.0,24 Stocks Moving In Monday's Pre-Market Session,2019-04-01 08:14:00-04:00,ELGX,neutral
416378.0,Endologix Sees Q1 19 Revenue $35M versus $34M Est.,2019-04-01 07:31:00-04:00,ELGX,neutral
416379.0,58 Biggest Movers From Yesterday,2019-03-07 04:55:00-05:00,ELGX,neutral
416380.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-03-06 12:27:00-05:00,ELGX,neutral
416381.0,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",2019-03-06 07:39:00-05:00,ELGX,negative
416382.0,"Endologix Reports Shareholders Approved Stock Split Of Not Less Than 1-For-5, Not More Than 1-For-10, Effective Mar. 6, 2019",2019-03-05 16:39:00-05:00,ELGX,positive
416383.0,Endologix Reaffirms Q1 Sales ~$35M; FY19 Sales Guidance At Least $140M,2019-02-25 16:26:00-05:00,ELGX,neutral
416384.0,"Endologix Q4 EPS $(0.26) Misses $(0.20) Estimate, Sales $34.693M Beat $31.99M Estimate",2019-02-25 16:25:00-05:00,ELGX,negative
416385.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,ELGX,neutral
416386.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,ELGX,positive
416387.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,ELGX,negative
416388.0,Endologix Announces its CE Mark for the Nellix EndoVascular Aneurysm Has Been Suspended,2019-01-22 16:03:00-05:00,ELGX,negative
416389.0,Endologix shares are trading higher after the company announced it anticipates Q1 revenue to beat the $31.9 million estimate.,2019-01-07 09:29:00-05:00,ELGX,positive
416390.0,Endologix Sees Q1 Sales $35.0M vs $31.93M Est,2019-01-07 08:04:00-05:00,ELGX,neutral
416391.0,Endologix,2019-01-07 08:03:00-05:00,ELGX,neutral
416392.0,Endologix Sees FY2018 Sales $155.80M vs $152.79M Est,2019-01-07 08:02:00-05:00,ELGX,neutral
416393.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ELGX,negative
416394.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,ELGX,positive
416395.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,ELGX,negative
416396.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ELGX,positive
416397.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,ELGX,neutral
416398.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,ELGX,neutral
416399.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,ELGX,negative
416400.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:21:00-05:00,ELGX,negative
416401.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,ELGX,neutral
416402.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,ELGX,negative
416403.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,ELGX,negative
416404.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,ELGX,negative
416405.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,ELGX,positive
416406.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,ELGX,neutral
416407.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,ELGX,negative
416408.0,"Endologix Raises FY18 GAAP EPS Outlook From $(1.12)-$(1.04) to $(0.91)-$(0.87) vs $(0.79) Est., Sales $150M-$155M vs $151.74M Est.; Sees FY19 Sales $140M",2018-11-01 16:27:00-04:00,ELGX,neutral
416409.0,"Endologix, Inc. Q3 EPS $(0.12) Beats $(0.23) Estimate, Sales $34.8M Beat $32.84M Estimate",2018-11-01 16:25:00-04:00,ELGX,neutral
416410.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,ELGX,negative
416411.0,66 Biggest Movers From Yesterday,2018-10-26 05:21:00-04:00,ELGX,neutral
416412.0,60 Stocks Moving In Thursday's Mid-Day Session,2018-10-25 12:55:00-04:00,ELGX,neutral
416413.0,Endologix Prices $20M Common Stock Offering,2018-10-25 10:16:00-04:00,ELGX,neutral
416414.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,ELGX,negative
416415.0,Endologix Reports $20M Common Stock Offering,2018-10-24 16:03:00-04:00,ELGX,neutral
416416.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,ELGX,negative
416417.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,ELGX,positive
416418.0,"Stocks Which Set New 52-Week Low Friday, October 5th",2018-10-08 09:27:00-04:00,ELGX,negative
416419.0,FDA On Friday Classified Previous Endologix AFX Safety Notice As Class I Recall,2018-10-08 07:36:00-04:00,ELGX,positive
416420.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-10-03 13:09:00-04:00,ELGX,neutral
416421.0,Mid-Day Market Update: Dow Up 130 Points; Kala Pharmaceuticals Shares Slide,2018-10-03 12:22:00-04:00,ELGX,positive
416422.0,Mid-Morning Market Update: Markets Open Higher; Lennar Earnings Top Expectations,2018-10-03 10:16:00-04:00,ELGX,positive
416423.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-10-03 08:10:00-04:00,ELGX,neutral
416424.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,ELGX,positive
416425.0,"8 Stocks To Watch For October 3, 2018",2018-10-03 04:46:00-04:00,ELGX,neutral
416426.0,7 Stocks Moving In Tuesday's After-Hours Session,2018-10-02 16:39:00-04:00,ELGX,neutral
416427.0,UPDATE: Endologix Narrows FY18 Sales Guidance From $145M-$155M to $150M-$155M vs $149.8M Estimate,2018-10-02 16:03:00-04:00,ELGX,neutral
416428.0,Endologix Raises Low End Of FY18 Sales Guidance,2018-10-02 16:03:00-04:00,ELGX,negative
416429.0,Endologix Reports Q3 Prelim. Sales $34.3M-$34.7M vs $31.13M Est.,2018-10-02 16:02:00-04:00,ELGX,neutral
416430.0,"Stocks Which Set New 52-Week Low Yesterday, September 20th",2018-09-21 08:19:00-04:00,ELGX,negative
416431.0,"Stocks Which Set New 52-Week Low Yesterday, September 19th",2018-09-20 11:26:00-04:00,ELGX,negative
416432.0,"The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering",2018-09-19 08:47:00-04:00,ELGX,negative
416433.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,ELGX,negative
416434.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,ELGX,negative
416435.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,ELGX,negative
416436.0,51 Biggest Movers From Yesterday,2018-09-11 05:05:00-04:00,ELGX,neutral
416437.0,"Stocks Which Set New 52-Week Low Friday, September 7th",2018-09-10 16:38:00-04:00,ELGX,negative
416438.0,"Stocks Which Set New 52-Week Low Friday, August 31st",2018-09-04 10:32:00-04:00,ELGX,negative
416439.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,ELGX,positive
416440.0,"Stocks Which Set New 52-Week Low Yesterday, August 23rd",2018-08-24 09:12:00-04:00,ELGX,negative
416441.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,ELGX,negative
416442.0,"Stocks Which Set New 52-Week Low Yesterday, August 14th",2018-08-15 12:34:00-04:00,ELGX,negative
416443.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,ELGX,negative
416444.0,Endologix Appoints Jeffrey S. Brown as COO,2018-08-15 08:00:00-04:00,ELGX,neutral
416445.0,58 Biggest Movers From Yesterday,2018-08-15 05:02:00-04:00,ELGX,neutral
416446.0,61 Biggest Movers From Friday,2018-08-13 06:43:00-04:00,ELGX,neutral
416447.0,Mid-Afternoon Market Update: Dow Down Over 250 Points; Medley Management Shares Spike Higher,2018-08-10 14:30:00-04:00,ELGX,positive
416448.0,60 Stocks Moving In Friday's Mid-Day Session,2018-08-10 13:27:00-04:00,ELGX,neutral
416449.0,Mid-Day Market Update: Avalon Holdings Rises Following Q2 Earnings; Endologix Shares Drop,2018-08-10 12:14:00-04:00,ELGX,neutral
416450.0,Mid-Morning Market Update: Markets Open Lower; Trade Desk Earnings Top Expectations,2018-08-10 10:14:00-04:00,ELGX,negative
416451.0,"Endologix shares are trading 42% lower at $2.75 after the company announced its quarterly financial results, with earnings per share coming in below consensus estimates, and lowered guidance.",2018-08-10 10:06:00-04:00,ELGX,positive
416452.0,PiperJaffray Downgrades Endologix to Neutral,2018-08-10 09:23:00-04:00,ELGX,neutral
416453.0,30 Stocks Moving In Friday's Pre-Market Session,2018-08-10 08:32:00-04:00,ELGX,neutral
416454.0,"Endologix Lowers FY18 Sales $170-$180M To $145-$155M vs $175M Est., Lowers EPS From $(0.95)-$(0.89) To $(1.12)-$(1.04) vs $(0.58) Est.",2018-08-09 16:04:00-04:00,ELGX,negative
416455.0,"Endologix Q2 EPS $(0.28) Misses $(0.15) Estimate, Sales $44.74M Beat $44.45M Estimate",2018-08-09 16:02:00-04:00,ELGX,negative
416456.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,ELGX,positive
416457.0,40 Stocks Moving In Thursday's Pre-Market Session,2018-08-09 08:09:00-04:00,ELGX,neutral
416458.0,Endologix Reports 'Positive' 1-Year Results from the Ovation LUCY Study,2018-06-28 08:06:00-04:00,ELGX,neutral
416459.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,ELGX,neutral
416460.0,Endologix Appoints John Onopchenko as Chief Executive Officer,2018-05-02 16:24:00-04:00,ELGX,neutral
416461.0,Endologix Reaffirms FY18 Guidance,2018-05-02 16:14:00-04:00,ELGX,neutral
416462.0,"Endologix Q1 EPS $(0.24) Misses $(0.18) Estimate, Sales $42.3M Beat $41.27M Estimate",2018-05-02 16:14:00-04:00,ELGX,negative
416463.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,ELGX,neutral
416464.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,ELGX,neutral
416465.0,UPDATE: Endologix Says Results Of Aortic Trials Showed 'patients with larger aneurysms treated with EVAS had half the mortality at three years as compared to those treated with traditional EVAR systems',2018-04-25 10:02:00-04:00,ELGX,neutral
416466.0,Endologix Reports Results Of Late-Breaking Aortic Trials Session During Charing Cross Symposium: Showed 'significantly higher 3-year survival for EVAS patients',2018-04-25 10:01:00-04:00,ELGX,neutral
416467.0,"Seeing Notable Block Trade In Endologix Of 1.3M Shares At $4.10, Below Bid Of $4.23",2018-04-13 13:52:00-04:00,ELGX,negative
416468.0,15 Stocks Moving In Tuesday's Pre-Market Session,2018-03-20 08:20:00-04:00,ELGX,neutral
416469.0,7 Stocks Moving In Monday's After-Hours Session,2018-03-19 18:03:00-04:00,ELGX,neutral
416470.0,Endologix Shares Up 5.8% After Hours As Co. Reported Positive Results From ENCORE Analysis Of Several Prospective Clinical Trials And Registries Studying Polymer Endovascular Aneurysm Repair,2018-03-19 16:08:00-04:00,ELGX,positive
416471.0,Endologix Reports 'Positive' Results From Global ENCORE Analysis,2018-03-19 16:04:00-04:00,ELGX,neutral
416472.0,Endologix Reports John McDermott Will Step Down As CEO,2018-02-21 16:27:00-05:00,ELGX,neutral
416473.0,"Endologix Reports Q4 EPS $(0.17) vs $(0.21) Est., Sales $44M vs $44.9M Est.",2018-02-21 16:01:00-05:00,ELGX,neutral
416474.0,Endologix Q4 Earnings Preview,2018-02-21 10:50:00-05:00,ELGX,neutral
416475.0,JPMorgan Diagnoses The MedTech Space: Stock Picks And Pans,2018-01-02 15:45:00-05:00,ELGX,neutral
416476.0,JP Morgan Downgrades Endologix to Underweight,2018-01-02 06:18:00-05:00,ELGX,positive
416477.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,ELGX,neutral
416478.0,46 Stocks Moving In Wednesday's Mid-Day Session,2017-11-08 12:31:00-05:00,ELGX,neutral
416479.0,"Endologix Cuts FY17 Guidance, GAAP EPS from $(0.95) to $(0.91) to $(0.93) to $(0.91) vs $(0.62) Est., Sales from $185M-$190M to $181M-$184M vs $187.33M Est., Citing Slower Than Expected AFX2 Sales Recovery In The U.S.",2017-11-07 16:24:00-05:00,ELGX,negative
416480.0,"Endologix Reports Q3 Adj. EPS $(0.17) In-line with Est., Sales $46M vs $46.66M Est.",2017-11-07 16:22:00-05:00,ELGX,neutral
416481.0,Endologix Appoints John Onopchenko as COO,2017-10-19 08:00:00-04:00,ELGX,neutral
416482.0,Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate Nellix,2017-10-06 08:03:00-04:00,ELGX,positive
416483.0,Endologix Extends Its Winning Streak,2017-10-03 14:40:00-04:00,ELGX,positive
416484.0,Endologix Reports CE Mark Approval for the Nellix EndoVascular Aneurysm Sealing System,2017-09-21 08:00:00-04:00,ELGX,positive
416485.0,Endologix Reports Clinical Results From LEOPARD Study: Freedom From ARC With AFX/AFX2 Is 84.7%,2017-08-17 08:04:00-04:00,ELGX,positive
416486.0,"Endologix Sees FY17 GAAP EPS $(0.91-0.95) vs $(0.63) Est., Sales $185-190M vs $195.14M Est.",2017-08-02 16:11:00-04:00,ELGX,neutral
416487.0,"Endologix Reports Q2 EPS $(0.20) vs $(0.18) Est., Sales $46.8M vs $47.62M Est.",2017-08-02 16:09:00-04:00,ELGX,neutral
416488.0,Endologix Presents Positive Two-Year Clinical Data from the Nellix EVAS FORWARD IDE Trial at Society of Vascular Surgery 2017 Vascular Annual Meeting.,2017-06-03 12:20:00-04:00,ELGX,positive
416489.0,Endologix Reports Positive Clinical Data from the Ovation LUCY Study with 1.3% Major Adverse Event,2017-06-01 04:19:00-04:00,ELGX,positive
416490.0,"Endologix CEO McDermott  Buys 25,000 @ Avg Price: $4.45 -Form4",2017-05-30 13:08:00-04:00,ELGX,neutral
416491.0,"Endologix Director Guido J Neels Buys 20,000 @ Avg Price: $4.32 -Form4",2017-05-23 10:58:00-04:00,ELGX,neutral
416492.0,18 Biggest Mid-Day Losers For Thursday,2017-05-18 12:49:00-04:00,ELGX,negative
416493.0,Mid-Day Market Update: Ascena Retail Tumbles On Weak Guidance; athenahealth Shares Surge,2017-05-18 12:12:00-04:00,ELGX,negative
416494.0,FDA Approval For Endologix's Nellix Likely Pushed To At Least 2020,2017-05-18 11:58:00-04:00,ELGX,positive
416495.0,Analyst On Endologix: No Sense In Downgrading Now,2017-05-18 10:45:00-04:00,ELGX,negative
416496.0,Mid-Morning Market Update: Markets Mostly Higher; Wal-Mart Profit Tops Estimates,2017-05-18 10:10:00-04:00,ELGX,positive
416497.0,"Benzinga's Top Upgrades, Downgrades For May 18, 2017",2017-05-18 09:24:00-04:00,ELGX,positive
416498.0,Stifel Nicolaus Downgrades Endologix to Hold,2017-05-18 06:39:00-04:00,ELGX,neutral
416499.0,"UPDATE: Endologix Says Will Collaborate with FDA Over Coming Months on Study Protocol, Sees Starting Patient Enrollment in Q4'17, Sees PMA Approval in 2020",2017-05-17 16:47:00-04:00,ELGX,positive
416500.0,"Endologix Offers Update on Nellix System US Regulatory Status: Following Meeting with FDA, Co. Will Seek US Approval by Conducting Confirmatory Clinical Study with IFU, Gen2 Device Design",2017-05-17 16:46:00-04:00,ELGX,positive
416501.0,"Endologix Reports Q1 EPS $(0.26) vs $(0.21) Est., Sales $42.6M vs $41.11M Est.",2017-05-04 16:36:00-04:00,ELGX,neutral
416502.0,15 Stocks Moving In Monday's Pre-Market Session,2017-05-01 08:10:00-04:00,ELGX,neutral
416503.0,Endologix Enters $170M Credit Facility With Deerfield Management,2017-04-04 18:00:00-04:00,ELGX,positive
416504.0,Benzinga's Option Alert Recap From March 24,2017-03-24 16:15:00-04:00,ELGX,positive
416505.0,Option Alert: Endologix May 7.5 Calls: 1000 @  ASK  $0.65: 1122 traded vs 1261 OI:  Earnings 5/9 After Close (est)  $6.79 Ref,2017-03-24 14:27:00-04:00,ELGX,positive
416506.0,"Oppenheimer Annual Healthcare Conference Concludes Today; Presenters Include HCA, Axovant, Zynerba, Aquinox Pharma, TherapeuticsMD, Humana, Endologix",2017-03-22 09:16:00-04:00,ELGX,neutral
416507.0,"Endologix Reports Q4 EPS $(0.30) vs. $(0.19) Est., Rev. $47.46M vs. $48.69M",2017-02-22 16:14:00-05:00,ELGX,neutral
416508.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,ELGX,neutral
416509.0,Endologix Completes Patient Enrollment in the Ovation LUCY Study,2017-02-14 16:34:00-05:00,ELGX,neutral
416510.0,Key Presenters At Leerink's Healthcare Conference,2017-02-13 15:52:00-05:00,ELGX,neutral
416511.0,"Endologix Reports Reinstatement of CE Mark for AFX, AFX2 Endovascular AAA Systems",2017-01-25 12:00:00-05:00,ELGX,neutral
416512.0,Camber Capital Management Reports 7.07% Stake In Endologix,2017-01-23 16:12:00-05:00,ELGX,neutral
416513.0,Endologix Spikes to High of $6.90 on Volume Following PR,2017-01-17 10:31:00-05:00,ELGX,neutral
416514.0,Endologix Reports Resumption of Shipments of All Sizes of AFX 2 AAA Systems,2017-01-17 10:29:00-05:00,ELGX,neutral
416515.0,"Must Watch Stocks for December 30, 2016",2016-12-30 04:57:00-05:00,ELGX,neutral
416516.0,Mid-Afternoon Market Update: Gold Futures Up 1.5%; Endologix Shares Spike Higher,2016-12-29 14:22:00-05:00,ELGX,positive
416517.0,12 Biggest Mid-Day Gainers For Thursday,2016-12-29 12:19:00-05:00,ELGX,neutral
416518.0,Endologix Up 13% After Shipments Of Treatments For Aortic Disorders Resumed,2016-12-29 11:37:00-05:00,ELGX,neutral
416519.0,"Endologix Resumes Shipments, Procedures with AFX and Some Sizes of AFX2",2016-12-29 09:00:00-05:00,ELGX,neutral
416520.0,5 Stocks You Should Be Watching Today,2016-12-28 05:40:00-05:00,ELGX,neutral
416521.0,Mid-Afternoon Market Update: Ionis Pharma Rises After FDA Approval Of Spinraza; Seattle Genetics Shares Plummet,2016-12-27 14:30:00-05:00,ELGX,positive
416522.0,10 Biggest Mid-Day Losers For Tuesday,2016-12-27 12:55:00-05:00,ELGX,negative
416523.0,Mid-Day Market Update: Crude Oil Up Over 1%; Endologix Shares Slide,2016-12-27 12:17:00-05:00,ELGX,negative
416524.0,Mid-Morning Market Update: Markets Open Higher; Groupe Casino Offers To Buy Cnova,2016-12-27 10:03:00-05:00,ELGX,neutral
416525.0,UPDATE: Endologix Says AFX Endovasucalar AA System Shipments To Be Put On Hold,2016-12-27 07:31:00-05:00,ELGX,neutral
416526.0,Endologix Reports Temporary Hold on AFX to Resolve a Manufacturing Issue,2016-12-27 07:30:00-05:00,ELGX,positive
416527.0,"Endologix Halted, News Pending",2016-12-27 07:28:00-05:00,ELGX,neutral
416528.0,Endologix Receives Australian Therapeutic Goods Administration Approval for AFX2 Bifurcated Endograft System,2016-12-19 09:01:00-05:00,ELGX,positive
416529.0,15 Biggest Mid-Day Losers For Tuesday,2016-12-13 12:53:00-05:00,ELGX,negative
416530.0,Stocks Hitting 52-Week Lows,2016-12-13 10:48:00-05:00,ELGX,negative
416531.0,"Endologix Shares Down 6.5% Off The Open, Earlier, Co. Received Suspension Of CE Mark For AFX System",2016-12-13 09:41:00-05:00,ELGX,positive
416532.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-12-13 08:30:00-05:00,ELGX,neutral
416533.0,10 Stocks With Lowest Close In Three Weeks,2016-12-07 07:07:00-05:00,ELGX,negative
416534.0,10 Stocks With Lowest Close In Three Weeks,2016-11-30 06:55:00-05:00,ELGX,negative
416535.0,Mid-Day Market Update: Abercrombie & Fitch Drops After Downbeat Earnings; Synutra Shares Spike Higher,2016-11-18 12:16:00-05:00,ELGX,positive
416536.0,Mid-Morning Market Update: Markets Mostly Flat; Foot Locker Profit Beats Estimates,2016-11-18 10:04:00-05:00,ELGX,positive
416537.0,Endologix Sees FDA Approval Of Nellix Remaining Elusive; BMO Downgrades,2016-11-17 11:40:00-05:00,ELGX,positive
416538.0,Canaccord Genuity Medical Technology And Diagnostics Forum Today,2016-11-17 09:56:00-05:00,ELGX,neutral
416539.0,"BMO Capital Downgrades Endologix, Inc. - Common Stock to Market Perform",2016-11-17 09:08:00-05:00,ELGX,neutral
416540.0,"Companies Holding Analyst/Investor Days Today Include OncoSec Medical, F5 Networks, Infinera, Qualys, Becton Dickinson & Co, Catabasis Pharmaceuticals, Endologix, Vista Outdoor, And Paratek Pharmaceuticals",2016-11-17 08:30:00-05:00,ELGX,neutral
416541.0,10 Stocks With Lowest Close In Three Weeks,2016-11-17 06:40:00-05:00,ELGX,negative
416542.0,Mid-Afternoon Market Update: StemCells Climbs On Asset Purchase Agreement; Endologix Shares Drop,2016-11-16 14:30:00-05:00,ELGX,positive
416543.0,Endologix Falls On 2-Year Follow-Up Request,2016-11-16 14:25:00-05:00,ELGX,neutral
416544.0,12 Biggest Mid-Day Losers For Wednesday,2016-11-16 12:48:00-05:00,ELGX,negative
416545.0,Mid-Day Market Update: Dow Falls 75 Points; Shipping Stocks Spike Higher,2016-11-16 12:04:00-05:00,ELGX,neutral
416546.0,"JP Morgan Downgrades Endologix, Inc. - Common Stock to Neutral",2016-11-16 10:16:00-05:00,ELGX,positive
416547.0,"Endologix Reports Presentation of Five-Year Safety, Efficacy Data from Ovation Pivotal Trial at VEITH Symposium",2016-11-16 10:01:00-05:00,ELGX,positive
416548.0,UPDATE: Endologix Says FDA Requested Co. Provide Two-Year Patient Follow-Up Data from EVAS-FORWARD IDE Study of Nellix System,2016-11-16 09:01:00-05:00,ELGX,neutral
416549.0,Endologix Offers Update on Nellix PMA Process,2016-11-16 09:00:00-05:00,ELGX,neutral
416550.0,Endologix Shares Halted News Pending,2016-11-16 08:56:00-05:00,ELGX,positive
416551.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,ELGX,neutral
416552.0,"Endologix Reports Q3 Loss/Share $0.18 vs Est Loss/Share $0.15, Revenue $52.1M vs $51.83M Est",2016-11-01 17:00:00-04:00,ELGX,neutral
416553.0,Endologix Appoints Dr. Matthew Thompson as Chief Medical Officer,2016-10-25 09:00:00-04:00,ELGX,neutral
416554.0,"UPDATE: Endologix Study for Ovation Showed Low Major Adverse Event Rate of 0.4%, No Ruptures, Conversion or Secondary Interventions",2016-09-20 12:11:00-04:00,ELGX,negative
416555.0,Endologix Offers Data from Ovation LIFE Study: Showed Study Met Primary Endpoint,2016-09-20 12:11:00-04:00,ELGX,neutral
416556.0,"Leerink Swann Initiates Coverage on Endologix at Market Perform, Announces $13.00 PT",2016-09-06 06:36:00-04:00,ELGX,neutral
416557.0,Endologix Reports First Patients Treated with Ovation Alto Abdominal Stent Graft System,2016-08-17 09:00:00-04:00,ELGX,neutral
416558.0,Mid-Afternoon Market Update: Genworth Financial Rises On Earnings Beat; Cray Shares Slide,2016-08-03 14:42:00-04:00,ELGX,positive
416559.0,"Piper Jaffray Rates Endologix Overweight, Thinks Nellix Aneurysm Treatment Is 'Highly Approvable'",2016-08-03 14:05:00-04:00,ELGX,negative
416560.0,Mid-Day Market Update: Crude Oil Up 2.5%; Rubicon Project Shares Tumble Following Disappointing Outlook,2016-08-03 12:03:00-04:00,ELGX,negative
416561.0,Mid-Morning Market Update: Markets Mostly Flat; Humana Profit Beats Estimates,2016-08-03 10:05:00-04:00,ELGX,positive
416562.0,Benzinga's Top Downgrades,2016-08-03 09:10:00-04:00,ELGX,positive
416563.0,RBC Capital Downgrades Endologix to Sector Perform,2016-08-03 04:06:00-04:00,ELGX,neutral
416564.0,Endologix Lowers FY16 EPS Guidance To Loss Of -$0.70 to -$0.75/Share vs Est Loss Of -$0.79/share,2016-08-02 16:09:00-04:00,ELGX,negative
416565.0,"Endologix Raises FY 16 Guidance: Sees Revenue $197M-$203M vs $198.18M Est, Up From $192M-$202M Prior Guidance",2016-08-02 16:08:00-04:00,ELGX,neutral
416566.0,"Endologix Reports Q2 Adj Loss -$0.13/Share vs Est Loss -$0.20/Share, Rev $51M vs $46.3M Est",2016-08-02 16:06:00-04:00,ELGX,negative
416567.0,BMO Capital Highlights This Week's MedTech Earnings,2016-08-01 15:14:00-04:00,ELGX,neutral
416568.0,BMO's Physician Survey Results Indicate Good Health Of Endologix,2016-07-07 13:40:00-04:00,ELGX,positive
416569.0,"The Market In 5 Minutes: Improved Jobless Claims, A Big Food Acquisition And Pepsi's Latest Earnings",2016-07-07 09:02:00-04:00,ELGX,positive
416570.0,"BMO Capital Upgrades Endologix to Outperform, Raises PT to $16.00",2016-07-07 07:18:00-04:00,ELGX,neutral
416571.0,Canaccord Says The Nellix 'Carrot' Should Drive Endologix Higher,2016-06-13 11:45:00-04:00,ELGX,neutral
416572.0,Benzinga's Top Upgrades,2016-06-13 09:07:00-04:00,ELGX,positive
416573.0,Canaccord Genuity Upgrades Endologix to Buy,2016-06-13 07:03:00-04:00,ELGX,neutral
416574.0,Endologix Reveals Positive Clinical Data From Nellix EVAS FORWARD-IDE Study,2016-05-26 12:12:00-04:00,ELGX,positive
416575.0,"EndoLogix EVAS FORWARD-IDE Study Meets Primary, Secondary Endpoints",2016-05-26 09:01:00-04:00,ELGX,neutral
416576.0,Endologix Completes Patient Enrollment in the Ovation LIFE Study,2016-05-16 09:13:00-04:00,ELGX,neutral
416577.0,Endologix Reaffirms FY 2016 Guidance,2016-05-09 16:10:00-04:00,ELGX,neutral
416578.0,"Endologix Q1 EPS ($0.69) vs ($0.24) est, Revenue $42.4M vs $38.78M est",2016-05-09 16:10:00-04:00,ELGX,neutral
416579.0,"JP Morgan Assumes Endologix at Overweight, Announces $11.00 PT, Believes Co On Cusp Of Another Significant Growth Phase",2016-04-04 06:36:00-04:00,ELGX,positive
416580.0,Endologix Reports First US Commercial Impact of AFX2 Bifurcated Endograft System,2016-02-29 09:02:00-05:00,ELGX,neutral
416581.0,"RBC Capital Maintains Outperform on Endologix, Lowers PT to $11.00",2016-02-23 06:36:00-05:00,ELGX,negative
416582.0,"Endologix Sees FY16 Sales $192M-$202M vs $193.5M Est., Adj. EPS $(0.80)-$(0.70) vs $(0.85) Est.",2016-02-22 16:17:00-05:00,ELGX,neutral
416583.0,"Endologix Reports Q4 EPS $(0.22) vs $(0.16) Est., Sales $39.2M vs $40M Est.",2016-02-22 16:16:00-05:00,ELGX,neutral
416584.0,Endologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan,2015-12-10 16:06:00-05:00,ELGX,positive
416585.0,"Endologix, Express, Rockwell Automation Lead After-Hours Movers To Close Holiday Week",2015-11-27 15:19:00-05:00,ELGX,positive
416586.0,"Endologix, TriVascular Tech Report Early Termination of HSR Waiting Period",2015-11-18 16:02:00-05:00,ELGX,neutral
416587.0,Option Alert: $ELGX Dec $10 Call; 2200 Contracts @$0.50; Ref $9.06,2015-11-17 10:12:00-05:00,ELGX,positive
416588.0,"Endologix VP Abraham Buys 2,500 Shares @$8.85/Share -Form 4",2015-11-03 13:31:00-05:00,ELGX,positive
416589.0,"Endologix Chairman Mcdermott Buys 20,000 Shares @$8.90/Share -Form 4",2015-11-03 11:10:00-05:00,ELGX,positive
416590.0,Mid-Afternoon Market Update: GrubHub Drops On Earnings Miss; Pacira Pharmaceuticals Shares Gain,2015-10-27 15:43:00-04:00,ELGX,positive
416591.0,Benzinga's Top Downgrades,2015-10-27 15:09:00-04:00,ELGX,positive
416592.0,Mid-Day Market Update: Heidrick & Struggles Jumps On Strong Results; Roadrunner Transportation Systems Shares Decline,2015-10-27 13:18:00-04:00,ELGX,positive
416593.0,Stocks Hitting 52-Week Lows,2015-10-27 10:42:00-04:00,ELGX,negative
416594.0,Mid-Morning Market Update: Markets Down; Ford Earnings Miss Views,2015-10-27 10:27:00-04:00,ELGX,negative
416595.0,Morning Market Losers,2015-10-27 10:08:00-04:00,ELGX,negative
416596.0,Morning Market Gainers,2015-10-27 09:54:00-04:00,ELGX,neutral
416597.0,BMO Capital Downgrades Endologix to Market Perform,2015-10-27 06:22:00-04:00,ELGX,neutral
416598.0,"Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders, $9.10/TriVascular Unit, Total $211M",2015-10-26 16:05:00-04:00,ELGX,positive
416599.0,"Endologix Reports Q3 Adj. EPS $(0.13) vs. Est. $(0.14), Rev. $38.231M vs. Est. $38.12M",2015-10-26 16:04:00-04:00,ELGX,neutral
416600.0,Benzinga's Top Initiations,2015-10-19 09:51:00-04:00,ELGX,positive
416601.0,RBC Capital Initiates Coverage on Endologix at Outperform,2015-10-19 07:12:00-04:00,ELGX,neutral
416602.0,Endologix Reports FDA Approval of AFX(R)2 Bifurcated Endograft System,2015-10-12 09:01:00-04:00,ELGX,positive
416603.0,BTIG Research Upgrades Endologix to Buy,2015-09-28 05:49:00-04:00,ELGX,neutral
416604.0,Endologix Names Vaseem Mahboob CFO,2015-09-17 08:01:00-04:00,ELGX,neutral
416605.0,"Piper Jaffray Suggests Taking Advantage of Recent Pullback in Endologix Shares to Build Positions Ahead of Nellix IDE Data, US Launch",2015-08-25 08:39:00-04:00,ELGX,positive
416606.0,Oppenheimer Upgrades Endologix to Outperform,2015-08-07 07:35:00-04:00,ELGX,neutral
416607.0,"JP Morgan Upgrades Endologix to Overweight, Raises PT to $17.00",2015-08-06 07:35:00-04:00,ELGX,neutral
416608.0,Morning Market Losers,2015-08-04 09:57:00-04:00,ELGX,negative
416609.0,Benzinga's Top Downgrades,2015-08-04 09:32:00-04:00,ELGX,positive
416610.0,Canaccord Genuity Downgrades Endologix to Hold,2015-08-04 07:20:00-04:00,ELGX,neutral
416611.0,Endologix Sees FY15 Adj. Loss of $0.64-$0.59/Share vs Loss of $0.54/Share Est.,2015-08-03 16:15:00-04:00,ELGX,negative
416612.0,"Endologix Reports Q2 (0.19) vs. Est. (0.13), Rev. $39.5M vs. Est. $39.35M",2015-08-03 16:15:00-04:00,ELGX,neutral
416613.0,Endologix Reports 'Promising' Early Clinical Data from Nellix EVAS Forward-IDE Study,2015-06-17 11:01:00-04:00,ELGX,neutral
416614.0,"Endologix Earlier Reported Q1 Adj. Loss of $0.14/Share vs Loss of $0.13/Share Est., Sales $36.7M",2015-04-29 17:44:00-04:00,ELGX,negative
416615.0,"Endologix Reports Transition As Shelley Thunen Resigns, Will Stay For Transition",2015-03-12 09:01:00-04:00,ELGX,negative
416616.0,"Endologix Reports Q4 -$0.22 Vs Est -$0.10, Sales $38.8M Vs Est $38M",2015-02-25 16:09:00-05:00,ELGX,neutral
416617.0,Endologix Completes Patient Enrollment In The Nellix EVAS FORWARD-IDE Clinical Trial,2014-11-18 07:04:00-05:00,ELGX,neutral
416618.0,Endologix Completes Patient Enrollment in Nellix EVAS FORWARD-IDE Clinical Trial,2014-11-18 07:04:00-05:00,ELGX,neutral
416619.0,"Endologix Chairman Mcdermott Buys 25,000 Shares @$11.25/Share -Form 4",2014-11-05 15:13:00-05:00,ELGX,positive
416620.0,"Endologix, Inc. Reports Q3 EPS of $(0.13), Inline; Revenue of $37.15M vs $36.99M Est",2014-10-30 16:19:00-04:00,ELGX,neutral
416621.0,Deerfield Management Reports 6.70% Passive Stake in Endologix ,2014-10-14 06:25:00-04:00,ELGX,positive
416622.0,Stocks Continue Lower On Merger Monday,2014-09-29 17:24:00-04:00,ELGX,negative
416623.0,Endologix Drops On Weak Forecast; TIBCO Software Shares Spike Higher,2014-09-29 14:59:00-04:00,ELGX,negative
416624.0,"Midday Losers From September 29 - Tonix Pharmaceuticals Holding Corp., Digital Ally, Inc. And More",2014-09-29 13:58:00-04:00,ELGX,negative
416625.0,Markets Open Lower; Encana To Acquire Athlon Energy For $5.93 Billion,2014-09-29 11:14:00-04:00,ELGX,neutral
416626.0,Morning Market Losers ,2014-09-29 09:48:00-04:00,ELGX,negative
416627.0,"Endologix, Inc. Reports Prelim. Q3 Sales $37.0M vs $37.70M Est",2014-09-29 07:09:00-04:00,ELGX,neutral
416628.0,"Endologix, Inc. Lowers FY2014 EPS Guidance from $(0.27)-(0.33) to $(0.37)-(0.43) vs $(0.29) Est; Sees Sales $145.0M-148.0M vs $151.0M Est",2014-09-29 07:09:00-04:00,ELGX,negative
416629.0,Analysts At BTIG Confident In Endologix Following Meeting With Top Executives,2014-08-25 15:42:00-04:00,ELGX,positive
416630.0,Benzinga's Top Upgrades,2014-08-25 08:55:00-04:00,ELGX,positive
416631.0,"BTIG Research Upgrades Endologix To Buy, Shares Gain",2014-08-25 08:41:00-04:00,ELGX,positive
416632.0,"BTIG Research Upgrades Endologix, Inc. to Buy, Announces $17.00 PT",2014-08-25 07:49:00-04:00,ELGX,neutral
416633.0,Upcoming Corporate Events/Presentations for the Week of Aug. 11-15th,2014-08-11 11:54:00-04:00,ELGX,neutral
416634.0,Endologix Reports Q2 Earnings of -$0.06/Share on Revenue of $28M,2014-07-30 16:07:00-04:00,ELGX,neutral
416635.0,"BTIG Research Downgrades Endologix, Inc. to Neutral",2014-07-07 08:06:00-04:00,ELGX,neutral
416636.0,UPDATE: Credit Suisse Initiates Coverage On Endologix On Positive Outlook For Nellix,2014-06-30 09:15:00-04:00,ELGX,positive
416637.0,Endologix Reports Sales Milestone for Nellix(R) EndoVascular,2014-06-17 09:03:00-04:00,ELGX,neutral
416638.0,"JP Morgan Initiates Coverage on Endologix, Inc. at Neutral, Announces $15.00 PT",2014-05-12 06:12:00-04:00,ELGX,positive
416639.0,"Endologix, Inc. Sees FY2014 EPS $(0.22)-(0.35); Sees Sales $146.0M-152.0M",2014-04-30 16:38:00-04:00,ELGX,neutral
416640.0,"Endologix, Inc. Reports Q1 EPS of $(0.08), Inline; Revenue of $33.30M vs $32.24M Est",2014-04-30 16:37:00-04:00,ELGX,neutral
416641.0,"Endologix, Terso Partner for Fully Automated Nellix Inventory",2014-04-29 13:53:00-04:00,ELGX,neutral
416642.0,"BTIG Research Upgrades Endologix, Inc. to Buy, Announces $15.00 PT",2014-03-21 07:55:00-04:00,ELGX,neutral
416643.0,"Mid-Afternoon Market Update: Markets Take a Sharp Dip to the Downside, as Traders Take Month-End Profits",2014-02-28 16:00:00-05:00,ELGX,positive
416644.0,Mid-Day Market Update: Dow Surges Over 100 Points; Deckers Shares Slip After Disappointing Outlook,2014-02-28 13:30:00-05:00,ELGX,negative
416645.0,"Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr",2014-02-28 10:40:00-05:00,ELGX,neutral
416646.0,Mid-Morning Market Update: Markets Rise; Pepco Posts Higher Profit,2014-02-28 10:22:00-05:00,ELGX,positive
416647.0,"UPDATE: Endologix Last Night Reported Q4 GAAP Loss of $0.05/Share vs Loss of $0.02/Share Est., Sales $35.2M vs $36.9M Est.; Said Expecting FY14 Sales $146-152M vs $161.2M  Est.",2014-02-28 08:56:00-05:00,ELGX,negative
416648.0,"Endologix Shares Fall 25% Premarket on Lowered Guidance, Analyst Downgrades",2014-02-28 08:47:00-05:00,ELGX,positive
416649.0,"Oppenheimer Downgrades Endologix, Inc. to Market Perform, Lowers PT to $16.00",2014-02-28 07:53:00-05:00,ELGX,negative
416650.0,"BTIG Research Downgrades Endologix, Inc. to Neutral, Removes $21.00 PT",2014-02-28 07:52:00-05:00,ELGX,neutral
416651.0,Endologix Announces US Launch of Vela(TM) Proximal Endograft,2014-02-10 09:02:00-05:00,ELGX,neutral
416652.0,Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial,2014-01-21 09:02:00-05:00,ELGX,neutral
416653.0,"BTIG Research Initiates Coverage on Endologix, Inc. at Buy, Announces $21.00 PT",2014-01-08 08:52:00-05:00,ELGX,neutral
416654.0,Endologix Announces Offering of $75M of Convertible Notes,2013-12-03 16:03:00-05:00,ELGX,neutral
416655.0,Endologix Names Robert Mitchell as Pres,2013-11-22 16:09:00-05:00,ELGX,neutral
416656.0,UPDATE: BMO Capital Markets Reiterates on Endologix Following Stronger 3Q13 Estimates,2013-10-31 11:23:00-04:00,ELGX,positive
416657.0,"Stifel Nicolaus Maintains Buy on Endologix, Inc., Raises PT to $20.00",2013-10-31 08:28:00-04:00,ELGX,neutral
416658.0,"Endologix, Inc. Reports Q3 EPS of $(0.14) vs $(0.05) Est; Revenue of $33.30M vs $32.47M Est",2013-10-30 17:28:00-04:00,ELGX,neutral
416659.0,"Canaccord Genuity Initiates Coverage on Endologix, Inc. at Buy, Announces $19.00 PT",2013-08-07 09:25:00-04:00,ELGX,neutral
416660.0,Benzinga's Top Initiations,2013-08-07 09:23:00-04:00,ELGX,positive
416661.0,UPDATE: Canaccord Genuity Initiates Endologix at Buy on Multiple Positive Factors,2013-08-07 08:32:00-04:00,ELGX,positive
416662.0,"Canaccord Genuity Initiates Coverage on Endologix, Inc. at Buy, Announces $19.00 PT",2013-08-06 16:45:00-04:00,ELGX,neutral
416663.0,"Endologix, Inc. Reports Q2 EPS of $(0.03) vs $(0.06) Est; Revenue of $34.0M vs $33.92M Est",2013-07-30 16:18:00-04:00,ELGX,neutral
416664.0,"Endologix, Inc. Sees FY2013 Sales $128.0M-134.0M",2013-07-30 16:17:00-04:00,ELGX,neutral
416665.0,UPDATE: Stifel Nicolaus Initiates Endologix at Buy on Compelling Growth,2013-07-12 09:08:00-04:00,ELGX,positive
416666.0,"Stifel Nicolaus Initiates Coverage on Endologix, Inc. at Buy, Announces $18.00 PT",2013-07-12 07:42:00-04:00,ELGX,neutral
416667.0,"Market Wrap for Monday, July 1: Stocks Rise, But Finish Off Session Highs ",2013-07-01 16:21:00-04:00,ELGX,neutral
416668.0,"Endologix, Inc. Lowers Q2 EPS Guidance from $(0.14)-(0.17) to $(0.18)-(0.22) vs $(0.15) Est; Raises Q2 Sales Guidance from $126.0M-133.0M to $128.0M-134.0M vs $130.20M Est",2013-07-01 08:08:00-04:00,ELGX,negative
416669.0,"Endologix Reports Q2 Prelim. Sales $34M, Raises Sales Guidance for FY; Says Will Conduct Testing, Meet with Regulatory Agencies",2013-07-01 08:06:00-04:00,ELGX,neutral
416670.0,Endologix Announces Preliminary Second Quarter 2013 Revenue Growth of 33% and Update to Ventana Program ,2013-07-01 08:03:00-04:00,ELGX,positive
416671.0,Oppenheimer Reiterates Outperform Rating on Endologix Following Management Meetings,2013-06-10 10:42:00-04:00,ELGX,neutral
416672.0,"Endologix, Inc. Sees FY2013 Sales $126.0M-133.0M vs $130.77M Est",2013-04-30 16:50:00-04:00,ELGX,neutral
416673.0,"Endologix, Inc. Reports Q1 EPS of $(0.07) vs $(0.06) Est; Revenue of $29.80M vs $29.20M Est",2013-04-30 16:50:00-04:00,ELGX,neutral
416674.0,Endologix Reports FDA Approval of First Percutaneous Indication forEndovascualr Abdominal Aortic Aneurysm Repair,2013-04-16 11:31:00-04:00,ELGX,positive
416675.0,"BMO Capital Maintains Outperform on Endologix, Inc., Raises PT to $18.00",2013-02-28 08:05:00-05:00,ELGX,neutral
416676.0,"Endologix, Inc. Sees FY2013 GAAP EPS $(0.14)-(0.17); Sees Sales $126.0M-133.0M vs $130.70M Est",2013-02-27 16:48:00-05:00,ELGX,neutral
416677.0,"Endologix, Inc. Reports Q4 EPS of $(0.26) vs $(0.03) Est; Revenue of $29.22M vs $29.02M Est",2013-02-27 16:46:00-05:00,ELGX,neutral
416678.0,Endologix Says Primary Trial Endpoint Met from PREVAR Randomized Trial,2013-01-28 08:33:00-05:00,ELGX,neutral
416679.0,"Endologix Reports Q4 Sales $29.2M vs $28.3M Est, FY Global Sales Guidance Moved from $104-106M to $105.9M",2013-01-07 09:06:00-05:00,ELGX,neutral
416680.0,Endologix Names Shelley Thunen CFO,2013-01-02 13:02:00-05:00,ELGX,neutral
416681.0,Endologix IntuiTrak Delivery System Receives Shonin Approval for Marketing in Japan,2012-12-31 09:01:00-05:00,ELGX,positive
416682.0,Endologix CFO to Retire,2012-12-04 09:01:00-05:00,ELGX,neutral
416683.0,Endologix Reports Q3 EPS $-0.03 vs $-0.04 Est; Revenues $26.7MN vs $26.33M Est,2012-10-25 17:57:00-04:00,ELGX,neutral
416684.0,Endologix Settles Patent Litigation With Cook Medical,2012-10-17 09:05:00-04:00,ELGX,negative
416685.0,Benzinga's Top Initiations,2012-09-07 07:23:00-04:00,ELGX,positive
416686.0,UPDATE: Piper Jaffray Upgrades Endologix to Overweight on Growth Profile  ,2012-08-09 08:18:00-04:00,ELGX,neutral
416687.0,"Piper Jaffray Upgrades Endologix from Neutral to Overweight, Maintains PT at $16",2012-08-09 06:22:00-04:00,ELGX,negative
416688.0,Lazard Capital Upgrades Endologix to Buy,2012-08-06 08:12:00-04:00,ELGX,neutral
416689.0,Endologix Reports Q2 EPS $-0.09 vs $-0.04 Est; Revenues $25.5M vs $25.23M Est,2012-07-26 16:29:00-04:00,ELGX,neutral
416690.0,Endologix Files Mixed-Secrities Shelf,2012-05-30 16:17:00-04:00,ELGX,neutral
416691.0,Endologix Announces Public Offering of 2.7 Million Shares of Common Stock ,2012-05-30 16:06:00-04:00,ELGX,positive
416692.0,Endologix Reports Q1 EPS $-0.07 vs $-0.06 Est; Revenues $24.5M vs $23.29M Est,2012-04-26 16:48:00-04:00,ELGX,neutral
416693.0,Endologix Chairman Franklin D. Brown to Retire ,2012-03-28 09:02:00-04:00,ELGX,neutral
416694.0,Endologix Appoints McDermott to Chairman; Brown to Retire,2012-03-28 09:01:00-04:00,ELGX,neutral
416695.0,UPDATE: Oppenheimer Raises Endologix's PT,2012-03-14 08:26:00-04:00,ELGX,neutral
416696.0,"Oppenheimer Maintains Endologix at Outperform, Raises PT from $14 to $17",2012-03-14 06:37:00-04:00,ELGX,neutral
416697.0,Weekly Traders Homework: Positive Jobs Report Gives Bullish Sentiment (w/ Economic Calendar and Stock Radar),2012-03-12 00:40:00-04:00,ELGX,positive
416698.0,Weekly Traders Homework: Small-Caps Correcting (w/ Economic Calendar and Stock Radar),2012-03-05 00:10:00-05:00,ELGX,neutral
416699.0,Endologix Reports Q4 EPS $(0.06) vs $(0.05) Est; Revenues $23.39M vs $23.67M Est	 				,2012-02-22 16:09:00-05:00,ELGX,neutral
416700.0,Endologix Completes Enrollment in PEVAR Randomized Trial  ,2012-02-09 08:20:00-05:00,ELGX,neutral
416701.0,Endologix Announces First Patient Treated in Ventana(TM) U.S. Clinical Trial ,2012-01-31 12:34:00-05:00,ELGX,neutral
416702.0,Notable Call Options Activity in Endologix,2012-01-27 12:48:00-05:00,ELGX,neutral
416703.0,5 Stocks On My Watch List,2012-01-25 17:54:00-05:00,ELGX,neutral
416704.0,Few small caps on the watch list,2012-01-24 17:48:00-05:00,ELGX,neutral
416705.0,Oppenheimer Names Endologix on December's Top Ideas ,2011-11-28 10:42:00-05:00,ELGX,positive
416706.0,UPDATE: Piper Jaffray Raises PT on Endologix to $12,2011-10-28 08:33:00-04:00,ELGX,neutral
416707.0,"Piper Jaffray Raises PT on Endologix from $10.50 to $12, Maintains Neutral",2011-10-28 07:12:00-04:00,ELGX,neutral
416708.0,Piper Jaffray Neutral on Endologix ,2011-09-28 07:36:00-04:00,ELGX,neutral
416709.0,Piper Jaffray Raises PT on Endologix to $10.50,2011-09-28 06:18:00-04:00,ELGX,neutral
416710.0,Afternoon Gainers; US Airways up +16%,2011-09-13 15:45:00-04:00,ELGX,neutral
416711.0,Endologix Receives IDE Approval for the Ventana Fenestrated Stent Graft System,2011-09-06 09:08:00-04:00,ELGX,positive
416712.0,Cook Medical Remains Resolute in Pursuit of Infringement Action Against Endologix Following Markman Ruling ,2011-08-18 16:58:00-04:00,ELGX,negative
416713.0,Endologix Announces Favorable Markman Ruling in Cook Patent Litigation,2011-08-17 09:15:00-04:00,ELGX,positive
416714.0,Hearing Chatter Endologix Upgraded at Lazard,2011-07-26 13:32:00-04:00,ELGX,neutral
416715.0,Endologix Spiking Higher on Upgrade at Lazard Captial,2011-07-26 13:31:00-04:00,ELGX,neutral
416716.0,Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows,2011-07-20 01:51:00-04:00,ELGX,positive
416717.0,Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products,2011-07-18 08:30:00-04:00,ELGX,positive
416718.0,Discovery Equity Partners Discloses 4.5% Stake in Endologix,2011-06-29 16:09:00-04:00,ELGX,neutral
416719.0,Top Percentage Gainers and Losers as of 2pm 6/24/11,2011-06-24 14:03:00-04:00,ELGX,negative
416720.0,Top Percentage Gainers and Losers as of 12:15pm 6/24/11,2011-06-24 12:17:00-04:00,ELGX,negative
416721.0,Endologix Inc Trading Higher on Heavy Volume,2011-06-24 11:46:00-04:00,ELGX,neutral
416722.0,Endologix Announces FDA Approval of AFX Endovascular AAA System ,2011-06-15 09:01:00-04:00,ELGX,positive
416723.0,Oppenheimer Raises Endologix Target from $10 to $11,2011-06-02 07:36:00-04:00,ELGX,neutral
416724.0,Endologix Guides FY 2011 Revenue $78M-$82M (ELGX),2011-04-21 16:10:00-04:00,ELGX,neutral
416725.0,Oppenheimer Surveys Non-Profit Hospitals' 1Q11,2011-04-06 07:25:00-04:00,ELGX,neutral
416726.0,Oppenheimer Maintains ELGX Outperform Rating,2011-03-24 08:07:00-04:00,ELGX,neutral
416727.0,Endologix Reports revised Q4 GAAP EPS of $0.22 vs. Previously Announced $0.15 ,2011-03-16 16:33:00-04:00,ELGX,neutral
416728.0,"Morning Market Movers (WBNK, DEP, BDCO, ELGX)",2011-02-23 10:01:00-05:00,ELGX,neutral
416729.0,Endologix Announces Presentation of Favorable Initial PEVAR Trial Results ,2011-02-15 11:52:00-05:00,ELGX,positive
416730.0,Robert W. Baird Initiates Endologix at Outperform (ELGX),2011-01-14 08:55:00-05:00,ELGX,neutral
416731.0,Endologix Appoints Guido Neels to Its Board,2010-12-20 09:06:00-05:00,ELGX,neutral
416732.0,Oppenheimer Initiates Outperform Rating on Endologix (ELGX),2010-12-15 09:21:00-05:00,ELGX,neutral
416733.0,Oppenheimer Initiating Coverage On Endologix (ELGX),2010-12-15 09:01:00-05:00,ELGX,neutral
416734.0,Oppenheimer Initiates Endologix At Outperform,2010-12-15 07:17:00-05:00,ELGX,neutral
416735.0,Zacks #5 Rank Additions for Tuesday - Tale of the Tape,2010-11-02 09:35:00-04:00,ELGX,neutral
416736.0,Endologix Reports 30% Third Quarter 2010 Revenue Growth: Loss of $0.01 per share,2010-10-27 16:24:00-04:00,ELGX,positive
416737.0,"CE Mark Approval for Endologix
 - Analyst Blog",2010-08-31 12:18:00-04:00,ELGX,positive
416738.0,Endologix Disputes Alleged Patent Infringement,2010-08-11 16:36:00-04:00,ELGX,negative
416739.0,Endologix to Present at the Jefferies 2010 Global Life Sciences Conference (ELGX),2010-06-01 16:38:00-04:00,ELGX,neutral
416740.0,"NASDAQ – Pre Market Five Most Advanced Stocks, ICOC, ELGX, SEAC, IIJI, ERII",2009-12-04 08:02:00-05:00,ELGX,positive
416741.0,"Benzinga’s Top Pre- Market Gainers (SEAC, IIJI, ELGX, TRGT, RYAAY, ERII)",2009-12-03 09:02:00-05:00,ELGX,positive
416742.0,"Today's Morning Top Gainers (SCIL, SRZ, IVAN, EGLX, HTZ)",2009-10-09 11:32:00-04:00,ELGX,positive
